News

Home / News
BASKET Study – NC762 in Subjects with Advanced or Metastatic Solid Tumors

BASKET Study – NC762 in Subjects with Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors This clinical study from NextCure, Inc., is a “first in human testing” study using a drug labeled NC762-01. This study is designed to evaluate the tolerability and benefits of NC762 in increasing doses to subjects with refractory solid tumors. NC762-01 is a new type of immunotherapy drug that will improve the immune system’s ability to control tumor development and growth. The FDA has approved seven immunotherapy drugs to date. There are still many patients who do not respond to these drugs....

Read More
BASKET Study – NC318 in Subjects with Advanced or Metastatic Solid Tumors

BASKET Study – NC318 in Subjects with Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors NC318 is a monoclonal antibody, a first in class immunomedicine that targets Siglec-5 (S15). S15 suppresses the immune system, specifically T cells which fight infection and cancer. NC318 blocks the immune system suppression caused by S15 and restores T cell function. NC318 not only restores T cell function and anti-tumor immunity. Many immunotherapies target the PD-1 (programed death) and PD-L1 (PD ligand) pathways to fight cancer. The PD-1 / PD-L1 and S15 pathways do not overlap so NC318 may be suited...

Read More
Gettysburg Cancer Center Expands Clinical Trial Resources With Help of OneOncology

Gettysburg Cancer Center Expands Clinical Trial Resources With Help of OneOncology

In an interview with Targeted Oncology™, Statish Shah, MD, the medical director of Gettysburg Cancer Center, discusses the OneOncology partnership in more detail and how it will benefit patients.  Gettysburg Cancer Center has joined OneOncology, allowing the community oncology center to expand services and clinical trial resources to its patients. Small community cancer centers play an important role in cancer management, especially in small, rural areas, according to Statish Shah, MD. For many rural patients, larger cancer centers can be hours away, being a huge detriment to care and patient outcomes. Small cancer centers can help provide care closer to...

Read More